Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.

H, Taheri; M, Malek; F, Ismail-Beigi; F, Zamani; M, Sohrabi; Babaei M, Reza; ME, Khamseh

doi:10.1007/s12325-020-01498-5

Public

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.

Shared by NobleBlocks on Sep 25, 2020 • 12:00 AM UTC

Authors:

Taheri H

Malek M

Ismail-Beigi F

Abstract

<h4>Introduction</h4>Despite the high prevalence of non-alcoholic fatty liver disease (NAFLD) and its associated co-morbidities, no efficient treatment in a high percentage of individuals is available. Beneficial effects of sodium-glucose co-transporter 2 inhibitors on fatty liver have been investig...

Subject

Liver fibrosis

Non-alcoholic fatty liver disease

Transient Elastography

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!